Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-6

First 6 Last

Share
Profile

Follow
thorndog

999 Posts.

191

30/05/22

10:06

Post #: 61696255
Share

Originally posted by moosey: ↑

Level 2, 66 Hunter Street

Sydney NSW 2000

Tel: (61-2) 9300 3344

Fax: (61-2) 9221 6333

E-mail: [email protected]

Website: www.biotron.com.au

30 May 2022

The Manager Companies

ASX Limited

20 Bridge Street

SYDNEY NSW 2000 (2 pages by email)

Dear Madam

POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM

The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’ has received

guidance from the U.S. Food and Drug Administrations (‘FDA’ for development of its lead antiviral

drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults.

The FDA’s guidance was received in written respons e to Biotron’s pre-IND briefing package and

request in March 2022, which include d an overview of preclinical a nd (HIV) clinical development,

and specific questions relating to re gulatory requirements for progressi on to filing an investigational

new drug (‘IND’ application for the COVID-19 indication.

Biotron sought guidance on the design of a proposed Phase 2 clinical trial in recently diagnosed

COVID-19 infected individuals and assurance that the preclinical data package and manufacturing

processes were sufficient to support this next stage of clinical development.

Biotron’s Managing Director, Dr Michelle Miller, said:

“The FDA responses were constructive, highly informative, and provide direction in the design of the

proposed Phase 2 clinical trial. The recommenda tions for a small, placebo-controlled, proof-of-

concept, dose-finding study, with agreed end points, in line with studies for other respiratory diseases,

including influenza, are very welcome. This design is de-risking and will provide the Company with

important time and resource savings.

The feedback on the existing sup porting non-clinical studies and the manufacturing processes,

specification and composition of the drug product was positive.

The design of regulatory-quality clinical studies for SARS-CoV-2 therapeutic advancement during this

currently evolving disease and treatment landscape, re quires careful considerat ion. We now have a

clear directive for the design of a Phase 2 study. This guidance will inform the on-going development

of BIT225 and subsequent next-generation follow-on drugs in Biotron’s portfolio.

The FDA responses indicate that we are on the right path to the clinic. Our confidence levels for this

new class of anti-SARS-Cov-2 drug remain high.”

Expand

just curious why you always post what's already posted at the top of announcements?

BIT Price at posting: 10.8¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group

I88

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

29M

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

PH2

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

Biden's exit bakes in a Kamala Harris ballot while markets expect Trump to win. How could equities fare this week?

There are more pages in this discussion • 467 more messages in this thread...

First 6 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 3.4¢		Change 0.000(0.00%)		Mkt cap ! $30.67M

Open	High	Low	Value	Volume
3.3¢	3.5¢	3.3¢	$12.66K	367.6K

Buyers (Bids)

No.	Vol.	Price($)
1	155931	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.6¢	113208	2

View Market Depth

No.	Vol.	Price($)
1	155931	0.034
2	303297	0.033
4	246250	0.032
2	330000	0.031
9	557366	0.030

Price($)	Vol.	No.
0.036	113208	2
0.037	537816	2
0.038	162500	1
0.039	317353	2
0.040	113240	2

Last trade - 16.10pm 22/07/2024 (20 minute delay)

BIT (ASX) Chart

Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-6

HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

Biden's exit bakes in a Kamala Harris ballot while markets expect Trump to win. How could equities fare this week?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-6

Top Stories

HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

Biden's exit bakes in a Kamala Harris ballot while markets expect Trump to win. How could equities fare this week?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News